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a  b  s  t r  a c  t
Cardiovascular disease is the leading cause of the death in dialysis patients. Arteriovenous
ﬁstulas (AVFs) are associated with lower mortality and are viewed as the desired access
option in most patients with advanced kidney disease needing dialysis. However, AVFs have
signiﬁcant and potentially deleterious effects on cardiac functions particularly in the set-
ting of preexisting heart disease. This article provides a comprehensive and contemporary
review to what is known about the impact of AVFs on: congestive heart failure, left ventri-
cular hypertrophy, pulmonary hypertension, right ventricular dysfunction, coronary artery
disease and valvular heart disease.
© 2015 The Authors. Published by Elsevier España, S.L.U. on behalf of Sociedad Española
de Nefrología. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Complicaciones  cardiacas  de  las  fístulas  arteriovenosas  en  pacientes  con
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r  e  s  u  m  e  n
La enfermedad cardiovascular es la principal causa de muerte en los pacientes dializados.
Las fístulas arteriovenosas (FAV) se asocian a una menor mortalidad y se consideran la
opción preferible de vía de acceso en la mayor parte de los pacientes con enfermedad
renal avanzada que requieren diálisis. Sin embargo, las FAV tienen efectos importantes
y potencialmente nocivos sobre las funciones cardíacas, en especial en presencia de una
cardiopatía preexistente. En este artículo se presenta una revisión completa y actualizada de
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los conocimientos existentes sobre las repercusiones que tienen las FAV en los trastornos de:
insuﬁciencia cardiaca congestiva, hipertroﬁa ventricular izquierda, hipertensión pulmonar,
disfunción ventricular derecha, enfermedad coronaria y valvulopatías cardíacas.
© 2015 The Authors. Publicado por Elsevier España, S.L.U. en nombre de Sociedad Española
de Nefrología. Este es un artículo Open Access bajo la licencia CC BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Cardiovascular disease is the leading cause of the death
in patients receiving chronic renal replacement therapy.1–3
Arteriovenous ﬁstulas (AVFs) have superior longevity, lower
infection and mortality rates and are associated with lower
cost, and hence have become the vascular access of choice for
patients needing dialysis.4 Indeed, the prevalence of AVFs in
the United States increased from 32% of all dialysis access in
2003 to 61% in 2012.5,6 Despite their association with a lower
mortality, AVFs have signiﬁcant effects on cardiac functions
predominantly related to the increase in preload and cardiac
output (CO). This article reviews the potential effects of the
creation and the ligation of AVFs on cardiac function and their
mechanisms.
It should be emphasized, at the outset, that determining
the exact effects of AVFs on cardiac functions is fraught with
problems for a couple of reasons: patients with end stage renal
disease (ESRD) requiring dialysis almost invariably have vol-
ume overload due to water and salt retention. They also have
pressure load due to arterial sclerosis and hypertension, and
increased CO secondary to chronic anemia. In addition, many
hemodialysis patients have signiﬁcant pre-existing myocar-
dial, valvular or coronary heart disease. It is, therefore, often
difﬁcult to tease out the exact contribution of an AVF to cardiac
dysfunction in hemodialysis patients. Nevertheless, worsen-
ing in cardiac functions soon after AVF creation has been
observed favoring a causative effect of the AVF on certain
cardiac functions. The current literature suggests that the
creation of AVF can cause or exacerbate the following con-
ditions: congestive heart failure, left ventricular hypertrophy,
pulmonary hypertension, right ventricular dysfunction, coro-
nary artery disease, and valvular dysfunction.
AVFs  and  congestive  heart  failure
Congestive heart failure (CHF) is highly prevalent among
patients with ESRD. Approximately 35–40% of patients with
ESRD have an established CHF diagnosis at initiation of
hemodialysis.1,3,7–9 Patients with ESRD and CHF have a far
worse prognosis than those without CHF.3,10 Since hemody-
namic optimization is the corner stone of managing patients
with ESRD as well as those with CHF, studying the hemody-
namic effects of AVFs in patients with ESRD with and without
CHF is a sensible task.
Long before we  utilized AVFs for hemodialysis access, the
hemodynamic effects of AVFs were studied in patients who
developed AVFs secondary to trauma AVFs. In these patients,
the development of an AVF was noted to be associated with
an apparent increase in CO.11,12 The introduction of the ‘man-
made’ AVFs for hemodialysis access provided more  insight
into the hemodynamic effects of these ﬁstulas: First, the
creation of an AVF leads to shunting of blood ﬂow from the
high resistance arterial system into the low resistance venous
system, with a subsequent rise in venous return and CO.13
Second, the presence of an AVF decreases arterial impedance
and thus lessens the left ventricular afterload. The lowering
of arterial impendence may also reduce the effective circu-
lating volume of the systemic circulation, activating arterial
baroreceptors, and leading to secondary increase in cardiac
sympathetic tone, contractility, and CO.14–16 The net effect of
AVFs is a signiﬁcant increase in CO.
Many studies investigated the impact of AVFs on
echocardiographic indices of cardiac morphology and
function.13,14,16–21 These studies consistently showed an
increase in LV end-diastolic dimension (LVEDD), contractility,
stroke volume and CO within 7–10 days after the surgical
construction of AVF.13,14,18 Diastolic ﬁlling parameters (E to A
ratio) were also impaired, indicative of worsening diastolic
functions. On average, the creation of an AVF increases
CO by 15–20% and left ventricular end-diastolic pressure
by 5–10%.16 Additionally, biomarkers secreted in response
to hypervolemia such as atrial naturietic peptide (ANP)
and brain naturietic peptide (BNP), are both substantially
increased,13,14 suggesting the presence of an cardiac volume
overload despite an optimal overall body volume status.
The impact of these physiological effects of AVF on the car-
diac function is controversial. While many  studies suggested
that the decreased vascular resistance and the increased CO
are predisposing factors for the development or the worsening
of heart failure,9 others suggested that the decrease in periph-
eral resistance and blood pressure with a parallel increase in
ejection fraction could be potentially beneﬁcial.22
Risk  of  worsening  heart  failure  after  AVF
There is no standard deﬁnition for high output CHF. The
literature is inconclusive with regards to the incidence of wors-
ening CHF after AVF creation. Most authors believe that the
incidence of high output CHF among hemodialysis patients
with AVFs is low, and that most patients with ESRD tolerate
AVFs.23,24 This belief is supported by the fact that the litera-
ture on high output CHF in ESRD patients is limited to case
reports and small series25–28 and that corrective measures
(AVF banding or surgical ligation) due to AVF-related cardiac
derangement are uncommon. Dixon et al. noted that the rate
of AVF banding due to worsening CHF in a cohort of 204
patients (322 accesses) was only 2.6%.29 On the other hand,
some authors suggest that high output CHF is not uncom-
mon  but is often overlooked.26,30 These authors argue that
when cardiac deterioration occur in hemodialysis patients, it
is usually attributed to the many  risk factors that are highly
prevalent in this population, and that the exact contribution of
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AVF to the worsening in cardiac functions is often not carefully
sought.1,3,7–9 This is especially in patients with a long-standing
AVFs, although AVF-related worsening CHF has been reported
up to 10 years after AVF formation.31
It should be emphasized that most ESRD patients tolerate
AVF well. However, given the deleterious outcomes in those
who  do not tolerate AVF, substantial efforts have been made
to identify that small fraction of patients who are at risk for
cardiac decompensation and high output CHF. There is com-
pelling evidence that the development of high output CHF
in ESRD patients with prior clinical or subclinical heart fail-
ure, is proportional to the vascular access ﬂow (Qa),29,32,33
Most cases of high output CHF were reported in patients with
Qa > 2 l/min.32 Upper arm (brachiocephalic) AVFs have twice
the ﬂow or lower arm (radiocephalic) AVFs.34 Macrae et al.
noted that the average Qa in upper arm AVFs among ESRD
patients enrolled in several studies was 1.13–1.72 l/min.33 In
the same cohort, 15% of patients had a Qa > 2 l/min. The ratio
of access ﬂow (Qa) to CO can be also be used to predict the
risk of worsening CHF. A functional upper arm AVF has an
average Qa/CO of 22%. Based on anecdotal experience, high
output heart failure was associated with a Qa/CO of >40% in
most cases.33 However, from an epidemiological point of view,
high Qa is not clearly associated with an increase in mortal-
ity. In an interesting study by Al-Ghonaim et al., there was no
increased risk of death at higher levels of Qa.35
Risk  of  developing  de  novo  heart  failure  after  AVF
Although some authors postulate that cardiac decompensa-
tion in ESRD patients with AVFs occurs only in individuals with
previously established chronic heart disease, there is evidence
that AVF creation is a major risk factor for developing a new
onset CHF.3,26,33,36 In the HEMO study, symptoms of CHF devel-
oped de novo during dialysis therapy in 17% of the patients.3
Albeit this could be purely due to the high prevalence of risk
factors for developing CHF in the ESRD population, an inde-
pendent effect of AVFs has been suggested. In an observational
study of 562 pre-dialysis patients, the creation of AVF was
more  predictive of the development of decompensated CHF
than a history of established CHF (odd ratio: 9.54 vs. 2.52,
respectively).36 The median time between the creation of the
AVF and the ﬁrst episode of CHF was 51 days (range: 26–138).
The location of AVF was, expectantly, closely related to the
incidence of new CHF (40% in brachio-cephalic vs. 8% in radio-
cephalic AVF).
AVFs  and  left  ventricular  hypertrophy
Left ventricular (LV) hypertrophy is highly prevalent among
patients with ESRD, and is a strong predictor of morbid-
ity and mortality.37,38 Although it is mainly a result of
chronic systemic hypertension, volume overload and ane-
mia, the presence of an AVF has a non-negligible effect on
LV hypertrophy.38 Arteriovenous ﬁstulas increase CO and lead
to signiﬁcant increases in both left ventricular wall mass and
diameter in the long-term.13,20,39,40 Furthermore, LV hypertro-
phy tends to persist in patients who had successful kidney
transplantation (KT) but have a remaining functional AVF.37,38
Closure of AVFs post-transplant has been shown to be associ-
ated with signiﬁcant regression of LV hypertrophy, despite the
observed post-closure increase in both systolic and diastolic
blood pressure.17,19,41,42 This regression in LV mass starts as
early as 3–10 weeks after ﬁstula closure and becomes more
pronounced at intermediate and long-term follow up.17,42
Although it is intuitive to speculate that regression of LV
hypertrophy will lead to fewer cardiovascular events, a direct
beneﬁcial effect has not been proven. In fact, some authors
believe that the potential beneﬁt of such regression in LV mass
after ﬁstula closure might be blunted by the observed shift
from a predominately eccentric hypertrophy to a predomi-
nantly concentric hypertrophy, a pattern that is known to be
associated with worse long term outcomes.17,19
AVFs  and  pulmonary  hypertension
Pulmonary hypertension (PH) complicates ESRD with a
prevalence of 12–45%.24,43 The presence of PH in the dial-
ysis population confers 2–3 folds increase in all-cause
mortality.43–45 In the majority of these patients, PH is post-
capillary (pulmonary venous hypertension – World Health
Organization Class II).46 Patients on hemodialysis have sev-
eral risk factors for developing PH: LV systolic and diastolic
dysfunction, volume overload, endothelial dysfunction and
sleep-discorded breathing.15 However, the presence of an AVF
has been shown to be an independent risk factor for the
development of PH in ESRD patients.23,43,47,48 Paneni et al.
compared echocardiography-derived peak systolic pulmonary
artery pressure (PAP) between patients undergoing peritoneal
dialysis (PD), and those receiving hemodialysis with radial
and brachial AVFs. Systolic PAP was 29.7 ± 6.7, 37.9 ± 6.7 and
40.8 ± 6.6 mm Hg, respectively (p < 0.001).47 In concordance
with these ﬁndings, several other studies found a much
less prevalence of PH in patients receiving PD compared to
matched cohorts of patients undergoing hemodialysis via
AVF.23,43,48,49 The mechanisms of AVF-related PH deserve more
scrutiny.
The  effects  of  volume  overload
As discussed previously, AVFs lead to decreased systemic
vascular resistances, increased venous return, and therefore
increased pulmonary blood and enhanced CO setting the stage
for load-related PH.13,14,17,18,20 This theory has been supported
by several studies that demonstrated a temporal relationship
between PAP rise and AVF creation.49–52 These studies also
showed a signiﬁcant association between both the duration
of AVF and the ﬁstula ﬂow with the severity of PH.49,50,52
Upper arm AVFs, known to have higher ﬂow than lower arm
AVFs, are associated with higher risk of developing PH.47,50
Compression of the AVFs by a sphygmomanometer,43,53 and
surgical closure of the AVFs,54 both induce a rapid decrease
in CO followed by a stable decrease in PAP. The late drop
in PAP could be more  pronounced than the initial drop
when manual compression of an AVF is undertaken. In a
case series of ﬁve patients in whom manual compression
of the AVF in the catheterization laboratory was performed
to predict a successful surgical closure, the chronic drop
in CO following surgical AVF closure was 4 fold greater
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than the fall in CO seen during acute manual compression
of the ﬁstula (F. Raza, personal communication). Contrary
to these ﬁndings, no association between the presence of
AVFs or ﬁstula ﬂow and PAP was found in two small
studies.23,24
Although AVF-associated volume overload seems to be the
prime mechanism in development of PH in the hemodialysis
population, the ability of an AVF alone to cause PH has been
questioned.43 The pulmonary circuit has an enormous capac-
ity and is usually able to tolerate signiﬁcant volume loads
before it decompensates. Hence, it has been proposed that in
patients who  develop PH after AVF creation, a baseline pul-
monary vascular dysfunction is present leading to failure of
the pulmonary circuit to accommodate the AVF-mediated ele-
vated CO.43 This assumption is supported by two observations:
(1) Patients without kidney disease or other signiﬁcant co-
morbidities are able to tolerate traumatic AVFs for a long time
before they develop symptoms of PH or heart failure.55–58 (2)
Kidney transplantation may revert PAP to normal in patients
who  still have a functioning AVF.53
Endothelial dysfunction has been suggested as an alterna-
tive or additive etiology for the development of pulmonary
hypertension in patients with AVF. The vascular endothelium
has complex and important physiological functions includ-
ing controlling the vascular tone.59,60 Several studies have
shown that patients with ESRD have impaired nitric oxide
(NO) production,61 and increased endothelin-1 (ET-1) activity62
both of which have been implicated in the pathophysiology
of PH.63 The impaired NO production in dialysis patients is
thought to be secondary to the reduced bioavailability of NO
substrate l-arginine, and the accumulation of endogenous
inhibitors of NO synthase.64 The lack of the vasodilator prop-
erties of NO could contribute to an increased vascular tone
and eventually to the causation of PH. Another potential cause
of endothelial dysfunction in dialysis patients is the vascular
wall shear stress associated with hemodialysis-related abnor-
mal  hemodynamics.62,65 In non-dialysis patients with chronic
left to right blood shunts (e.g. patients with congenital heart
disease), blood shunting augments wall shear stress which
leads to endothelial damage, vascular remodeling and PH.65,66
Similar effects can be suggested in hemodialysis patients with
functional AVFs.62,67
AVFs  and  right  ventricular  dysfunction
The prevalence and pathophysiology of PH in patients on
hemodialysis has been extensively studied. However, data on
the development of right ventricular (RV) dysfunction in ESRD
patients with AVF is scarce.
A few recent studies examined the effect of AVFs
on echocardiographic parameters of RV dysfunction.47,68,69
Paneni et al. studied the prevalence of RV dysfunction in 94
patients on hemodialysis and 26 patients on PD.47 In this
study, Tissue Doppler-derived myocardial performance index
(MPI) was used as an indicator of global RV function. Myocar-
dial performance index has been found to be more  sensitive
and less load-dependent than other echo indices in predict-
ing RV dysfunction and adverse clinical outcomes.70,71 Right
ventricular ejection fraction was  preserved in the majority
of patients across all subgroups. Right ventricular dysfunc-
tion (deﬁned with an MPI > 0.53) was, however, more prevalent
in hemodialysis patients compared with PD patients (71.3
vs. 34.6%, p < 0.001). The prevalence of RV dysfunction fur-
ther increased in patients with brachial AVF compared with
the radial access (90.6% vs. 61.3%, p < 0.001). Logistic regres-
sion analysis adjusting for confounding factors including PAP
showed that patients carrying AVFs displayed an increased
risk of RV dysfunction when compared to the PD group [OR:
6.3 (95% CI: 2.0–19.5), p < 0.001]. Again, the risk of RV dys-
function was further enhanced in patients with brachial AVF
compared to those with the radial ﬁstulas [OR: 5.9 (95% CI:
1.5–23.1), p < 0.05]. In another study of 41 HD patients with
AVFs, RV dysfunction (deﬁned by an MPI  of >0.55), was present
in 18 patients (44%).68 In keeping with the ﬁndings by Paneni
et al., the presence of AVF was associated with RV dysfunction
independent of PAP values. DiLullo et al. also demonstrated
that AVFs were associated with impaired RV systolic function
(assessed by tricuspid annular plane excursion – TAPSE) and
signiﬁcant RV chamber dilatation compared to those dialyzed
via central venous catheters.69
The presence of RV dysfunction independent of PAP val-
ues, argues against a major role for PH in the development
of RV dysfunction in ESRD patients.47,68 It also suggests
that AVF-dependent volume overload may by itself play a
major role in triggering RV dysfunction in patients undergoing
hemodialysis.47
AVFs  and  coronary  artery  disease
Signiﬁcant coronary artery disease (CAD) is found in 30–40%
of ESRD patients on hemodialysis.2,9,72 Compared with
non-dialysis CAD patients, those on hemodialysis have sub-
stantially higher cardiac mortality, and poorer outcomes when
undergoing percutaneous or surgical revascularization.73,74
The concern with AVFs in patients with CAD is three-fold:
(1) the potential to provoke silent subendocardial myocardial
ischemia due to increased oxygen demand and/or decrease
oxygen supply. (2) The possible negative impact of AVFs on
ipsilateral internal mammary  artery (IMA) bypass graft, due to
distal steal. (3) The interference of AVFs with cardiopulmonary
bypass in patients undergoing coronary artery bypass (CABG)
surgery.
Impact  of  AVF  on  coronary  ischemia
In dog studies, high-ﬂow AVFs were associated with decrease
subendocardial coronary perfusion mainly due to decreased
diastolic pressure and shortening of the diastolic period.75,76
An interesting study by savage et al. used ﬁltered non-ﬁstula
arm ﬁnger pressure recordings to examine the effects of AVFs
on myocardial oxygen supply and demand surrogates.18 Dia-
stolic pressure time index (DPTI), systolic pressure time index
(SPTI), and the DPTI/SPTI ratio were used as indirect measures
of myocardial supply, myocardial demand and subendocardial
perfusion, respectively. The increase in oxygen demand due to
the AVF-related increased CO was ameliorated by the decrease
in oxygen demand due to the decreased peripheral vascu-
lar resistance caused by the AVF. The net effect on cardiac
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oxygen demand was  neutral. However, cardiac oxygen supply
and, therefore subendocardial perfusion, were both signif-
icantly reduced in patients with functioning AVFs. Manual
compression of AVFs was associated with improved subendo-
cardial perfusion surrogates.18,77 Despite the methodological
limitations, these studies suggest a possible negative effect
of AVF on subendocardial perfusion. However, conﬁrma-
tory studies with invasive hemodynamic measurements or
advanced imaging tools have not been reported.
Impact  of  AVF  on  coronary  artery  bypass  grafting  (CABG)
In patients with ESRD who undergo hemodialysis via an upper
extremity AVF ipsilateral to the internal mammary  artery
(IMA) used for CABG, both the bypass graft and the ﬁstula
are supplied by the subclavian artery. During hemodialysis,
the AVF ﬂow is signiﬁcant, and can lead to shunting of blood
away from the IMA  graft (steal phenomenon). There are sev-
eral reports of symptomatic IMA  steal during dialysis session
in patients with upper arm (brachio-cephalic) AVFs.78,79 Using
echocardiography, Gaudino et al. elegantly demonstrated a
signiﬁcant decrease in IMA  ﬂow and hypokinesis of the ante-
rior wall  of the LV upon initiation of hemodialysis via an
ipsilateral AVF in ﬁve patients. Both of these ﬁndings were
reversed when the dialysis machine was  turned off.80 Con-
versely, using similar methodology, two studies found that
changes in the AVF ﬂow did not signiﬁcantly alter Doppler
ﬂow hemodynamics of either the ipsilateral or contralateral
in situ IMA.81,82
The clinical impact of this potential ‘steal’ phenomenon on
clinical outcomes was recently studied.83,84 Takami et al. ret-
rospectively compared outcomes of 155 hemodialysis patients
whose left anterior descending artery (LAD) was revascular-
ized with the IMA  ipsilateral to the AVF (ipsilateral group)
and those whose LAD was grafted with the IMA  opposite
to the ﬁstula (contralateral group).84 The overall 5-year sur-
vival and cardiac event-free rates were 58% and 74% in the
ipsilateral group vs. 65% and 68% in the contralateral group,
respectively (p = 0.90 and p = 0.07). A similar study by Feldman
et al. showed  comparable survival rates by higher non-fatal
cardiac events in the ipsilateral group compared with the
contralateral group (81.2% vs. 64%, p = 0.023).83 Despite the
conﬂicting evidence, it seems reasonable avoid, when possi-
ble, using an IMA  coronary artery bypass graft ipsilateral to
the AVF. Similarly, placing AVF in a patient with a function-
ing IMA  would be better performed on the contralateral upper
extremity.
Another cause for concern in hemodialysis patients with
AVFs who  are undergoing CABG is the possible interference
of AVFs with the integrity of the cardiopulmonary bypass
circuit. The excessive venous return to the heart due to
high-ﬂow AVFs, can compromise the myocardial protection
offered by cardiopulmonary bypass, and lead to impromptu
alterations in the surgical plan. In one case, the AVF had
to be tied off after CABG to allow successful weaning of
cardiopulmonary bypass.85 In another case, selective bicaval
cannulation was needed to prevent cardiac distention due to
the signiﬁcant left to right shunting of blood via a functional
AVF.86
AVFs  and  valvular  heart  disease
Valvular heart disease is common among patient on
hemodialysis with a prevalence of 39–43%.3 The majority of
valvular abnormalities (aortic stenosis, aortic regurgitation,
mitral regurgitation and tricuspid regurgitation) are sensi-
tive to volume overload. Despite that, data on the effects of
AVF-associated volume load on patients with valvular heart
disease is limited to patients with aortic stenosis (AS).87,88
Effects  of  AVF  on  aortic  stenosis
Signiﬁcant aortic stenosis is present in 3.3% of hemodialysis
patients >65 years of age compared with 1–2% in the general
population. Also, severe AS is rare in non-ESRD patients who
are less than 50 but occurs in 3% of ESRD patients of similar
age.89
There are two potential effects of AVFs on patients with
severe AS: (1) the coexistence of AS and an AVF could com-
plicate the assessment of the severity of aortic valve disease.
Cardiac output has signiﬁcant impact on the assessment of
transaortic valve gradient in AS.90 In a patient with ESRD
and suspected severe AS, manual compression of the AVF
dropped the mean transaortic valve gradient from 45 mmHg
to 30 mmHg.87 (2) The increase in CO associated with the cre-
ation of AVF can lead to acute or sub acute decompensation
in patients with signiﬁcant AS who had no symptoms or were
minimally symptomatic prior to AVF surgery.88
Is  closing  AVFs  beneﬁcial  to  the  heart?
Preserving dialysis access is a priority to both dialysis patients
and their physicians. Closing AVFs in patients undergoing
hemodialysis has been reserved for those with apparent
access failure or apparent access-related complications.29 The
management of AVFs in patients who underwent success-
ful KT is a topic of ongoing debate.91–93 Most transplant
physicians currently suggest that AVF closure is not rou-
tinely required in KT recipients with stable renal allograft
function.91,94 Others believe that AVF closure is associated
with signiﬁcant beneﬁcial effects on cardiac functions and
on allograft survival.17,19,93,95,96 The beneﬁt of AVF closure
should be weighed against the small but the known poten-
tial life threatening complications associated with the closure
procedure.97 A number of studies examined the effects of
spontaneous or planned post-KT AVF closure on echocar-
diographic indices (LV wall mass index, wall thickness, and
LVEDD). The potential impact of ﬁstula closure on clinical out-
comes was also investigated in a smaller number of studies.
A summary of these studies is provided in Table 1.
Effects  on  echocardiographic  parameters
Spontaneous closure of AVFs (due to thrombosis), can result
in a signiﬁcant reduction in CO, LV wall mass index (LVMI),
and LVEDD.96 Similar beneﬁts were observed in patients
who underwent planned surgical AVF closure due to graft
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Table 1 – A summary of studies examining the outcomes of spontaneous and planned AVF closure in kidney transplant recipients.
Study Design Number of
patients
Reason for
access
closure
Fistula
vintage
before KT
Follow up Echocardiographic parameters Clinical outcomes
Vajdic
Trampuz
et al.92
2013
Retrospective
single arm
(evaluation of
complica-
tions of
functional
AVF post-KT)
592 KT
patients
NR 42 months 48 months NR Complications
occurred in 74
patients (12.5%):
Painful thrombosis
43.2%
Growing aneurysms
27%
Venous
hypertension 8.1%
distal Hypoperfusion
8.1% cardiac failure
8.1%
Solaimani
et al.91
2012
Retrospective 23 with
functional
AVF vs. 17
with closed
AVF
Spontaneous
closure in 34
Planned
closure in 4*
(out of these
patients 17
were
included in
the study)
30 months 14 months Patients with closed AVF:
signiﬁcant reduction in IVS
(1.16 ± 0.11 vs.
1.10 ± 0.11 cm, p = 0.002) and
PW thickness (1.17 ± 0.11
vs. 1.10 ± 0.11 cm, p = 0.001)
thickness but no signiﬁcant
change in LVEDD
(4.87 ± 0.38 vs.
4.85 ± 0.47 cm, p > 0.05)
Patients with persistent
AVF: no difference
NR
Głowin´ski
et al.99
2012
Retrospective
case–controlled
9  matched
pairs
Spontaneous
closure in 4
planned
closure in 5
for cosmetic
reasons
24 months 11 months No signiﬁcant difference
after AVF closure in IVS and
PW thickness, LVEDD,
LVWMI in both groups
NR
Kurita et al.50
2011
Retrospective
single arm
30  functional
AVF and 3
with
functional
grafts
Planned
closure due
to refractory
heart failure
36  months 60 months No signiﬁcant difference
after AVF closure in IVS and
PW thickness, LVEDD,
LVWMI
70%  had
symptomatic
improvement
(responders).
Responders had
better early survival
but 5-years survival
was similar in both
groups
2
4
0
 
n
e
fr
o
lo
g
ia. 2
0
1
5;35(3):234–245
Table 1 – (Continued)
Study Design Number of
patients
Reason for
access
closure
Fistula
vintage
before KT
Follow up Echocardiographic parameters Clinical outcomes
Movilli et al.17
2010
Prospective
observational
35  with
functional
AVF and 25
with closed
AVF
Planned
closure due to
malfunction
56 months 6 months Patients with closed AVF:
signiﬁcant reduction in IVS
and PW thickness
(11.8 ± 2.1 vs. 11.0 ± 2.2 cm,
and 10.8 ± 1.7 vs.
10.0 ± 1.9 cm, p < 0.001).
LVEDD and LVWMI also
signiﬁcantly decreased
(51 ± 4 vs. 49 ± 4  and
135 ± 40 vs. 123 ± 23 g/m2).
p < 0.001 for all.
Patients with persistent
AVF: no difference
NR
Vajdic et al.93
2010
Retrospective
(evaluation of
effects of
persistent
AVF on
allografts
after KT)
239 with
functional
AVF and 72
with closed
AVF
Spontaneous
closure in 70
planned
closure in 2*
NR 70 months NR 5 years allograft
survival was 60% in
patients with
persistent AVF vs.
75% in those with
closed AVF
(p = 0.045). Persistent
AVF was an
independent risk
factor for allograft
loss (HR 1.336; 95%
CI, 1.018 –1.755;
p  = 0.037)
Cridlig et al.96
2008
Retrospective
case–controlled
38  matched
pairs
Spontaneous
closure in 23
Planned
closure in 4*
Previously
closed in 11
(9 on PD, 2
with
tunneled
catheters)
23 months 65 months Compared with those with
closed AVF, patients with
persistent AVF had: more
PW thickness (12.2 ± 1.7
vs.11.5 ± 1.8 cm, p = 0.007),
larger LVEDD
(52.1 ± 7.1 vs. 48.5 ± 6.0,
p = 0.02), and higher LVMI
(135.1 ± 30.3 vs.
112.4 ± 28 g/m2, p = 0.001).
NR
Sheashaa
et al.98
2004
Prospective
observational
34  with
functional
AVF and 17
with closed
AVF
Spontaneous
closure in all
17 months 12 months,
echo
120 months,
clinical
No difference in IVS and PW
thickness, LVEDD, and LVMI
between the two groups
No signiﬁcant
difference in death
or allograft survival
between the two
groups
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Table 1 – (Continued)
Study Design Number of
patients
Reason for
access
closure
Fistula
vintage
before KT
Follow up Echocardiographic parameters Clinical outcomes
Unger et al.19
2004
Prospective
observational
8  with
functional
AVF and 17
with closed
AVF
Planned
closure for
CHF (n = 10),
venous
hypertension
(n = 6), and/or
cosmetic
reasons (n = 5)
88 months 32 months Patients with closed AVF:
signiﬁcant reduction in
LVEDD (29.5 ± 3.4 vs.
26.2 ± 3.2 mm, p = 0.017) and
LVWMI 139 ± 44 to
117 ± 40 g/m2, p < 0.001) at
21 months. No signiﬁcant
difference in IVS and PW
thickness.
Patients with persistent
AVF: no difference
NR
VanDuijnhoven
et al.92
2001
Prospective
interven-
tional
22  with
functional
AVF
Planned
closures in all
** (excluded
CHF patients)
104 months 46 months After 3 months of AVF
closure:
Both LVEDD and LVWMI
decreased: (51.5 ± 5.8 vs.
49 ± 5.4 mm, p < 0.01) and
(135 ± 34 vs. 119.8 ± 23 g/m2,
p < 0.01), respectively. No
signiﬁcant difference in IVS
and PW thickness.
NR
Delima
et al.21
1999
Retrospective 39 with
functional
AVF and 22
with closed
AVF
Planned
closure for
cosmetic
reasons
within 2
months of KT
in all
62  months,
group I 36
months,
group II
14  months Compared with those with
closed AVF, patients with
persistent AVF had higher
LVEDD (52.7 ± 4.8 vs.
49.2 ± 4.6, p = 0.007). No
signiﬁcant difference in IVS
or PW thickness and
LVWMI.
NR
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dysfunction,17 cardiovascular deragments,19 or as part of a
research protocol.41 Contrary to these ﬁndings, other studies
found no signiﬁcant effects of spontaneous or planned AVF
closure on echocardiographic indices.21,91,94,98
Effects  on  clinical  outcomes
In a large cohort of patients who underwent KT, the inci-
dence of AVF-related complications requiring an intervention
was 12.5% at 4 years.92 In these patients, cardiac decom-
pensation and distal arm hypoperfusion constituted 16.2% of
all complications. Transplant allograft survival was positively
affected by AVF closure  in one study,93 but was not different
in another.98 In all-comers, AVF closure was not associated
with a mortality beneﬁt at 10 years.98 Only one study explored
the effects of AVF closure  on clinical outcomes in patients
with refractory heart failure.95 In this study 30 patients with
AVF and 3 with arteriovenous grafts were referred for access
closure due to refractory CHF. There was an immediate sig-
niﬁcant improvement in CHF symptoms in 70% of patients
(responders), but no beneﬁt was  seen in the other 30% (non-
responders). The non-responders had higher prevalence of
ischemic heart disease and longer durations since their AVF
creation. Those who responded had better survival at 1 year,
but had similar mortality rates as the non-responders at 5
years.
Conclusion
There are currently near 400,000 patients on hemodialysis and
180,000 kidney transplant recipients in the United States.6 The
majorities of these patients have cardiovascular disease and
have functional AVFs.1,2,5 Arteriovenous ﬁstulas are associ-
ated with lower mortality and are viewed as the desired access
option in most patients with ESRD needing dialysis.4 Arteri-
ovenous ﬁstulas are well tolerated by most patients. However,
the potentially deleterious effects of AVFs, particularly in the
setting of preexisting heart disease should not be underesti-
mated. A multidisciplinary evaluation of patients with known
heart disease before AVF creation is warranted. Additionally,
in patients who  develop dyspnea, heart failure, or pulmonary
hypertension, AVF revision should be considered as an impor-
tant therapeutic option, especially in those who underwent
successful kidney transplantation.
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